AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient ...

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...